Clinical characteristics and outcome of AML patients in the low and high IL-3Rα groups
| . | Low IL-3Rα . | High IL-3Rα . | Statistical evaluation . |
|---|---|---|---|
| No. patients | 23 | 20 | — |
| Median age, y (range) | 43 (30-67) | 57 (31-69) | P> .05 |
| Median WBC (×109/L) | 22.5 | 81.0 | P< .05 |
| Patients intensively treated | 20 | 14 | — |
| Complete response (%) | 14 (70) | 5 (36) | P < .05 |
| Resistant disease (%) | 3 (15) | 1 (7) | |
| Induction death (%) | 3 (15) | 8 (57) | P < .05 |
| Relapse | 6 of 14 | 4 of 5 | P< .05 |
| Continuous CR | 8 of 14 | 1 of 5 | P< .05 |
| Median CR duration (mo) | >24 (0-60+) | 6 (0-51) | — |
| . | Low IL-3Rα . | High IL-3Rα . | Statistical evaluation . |
|---|---|---|---|
| No. patients | 23 | 20 | — |
| Median age, y (range) | 43 (30-67) | 57 (31-69) | P> .05 |
| Median WBC (×109/L) | 22.5 | 81.0 | P< .05 |
| Patients intensively treated | 20 | 14 | — |
| Complete response (%) | 14 (70) | 5 (36) | P < .05 |
| Resistant disease (%) | 3 (15) | 1 (7) | |
| Induction death (%) | 3 (15) | 8 (57) | P < .05 |
| Relapse | 6 of 14 | 4 of 5 | P< .05 |
| Continuous CR | 8 of 14 | 1 of 5 | P< .05 |
| Median CR duration (mo) | >24 (0-60+) | 6 (0-51) | — |